Immunogenicity of the Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in patients with cirrhosis
<b>Conclusions</b>: A fifth mRNA-based COVID-19 booster dose significantly augments both humoral and cellular immunity in patients with liver cirrhosis. These findings support the use of a single annual booster dose to maintain adequate immune protection in this vulnerable population.
Authors
- Sinan Sharba (ORCID: https://orcid.org/0000-0003-0531-2137)
- Anna Martner (ORCID: https://orcid.org/0000-0002-6598-5221)
- Kristoffer Hellstrand (ORCID: https://orcid.org/0000-0002-6617-5976)
- J. Waldenström (ORCID: https://orcid.org/0000-0003-2234-0076)
- Samer Al-Dury (ORCID: https://orcid.org/0000-0002-5055-2327)
- Martin Lagging (ORCID: https://orcid.org/0000-0002-7995-3626)
- Johan Waern (ORCID: https://orcid.org/0000-0002-4481-3412)
- Johan Ringlander (ORCID: https://orcid.org/0000-0002-8483-6504)
- Sigrun Einarsdottir (ORCID: https://orcid.org/0000-0003-4756-6805)
- Amin Mountagui
- Hao Wang (ORCID: https://orcid.org/0000-0001-9425-4666)
- Ellen Fridriksson
- Linn Dahlsten Andius
Institutions
- Sahlgrenska University Hospital (SE)
- Region Västra Götaland (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Scandinavian Journal of Gastroenterology
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1080/00365521.2025.2518466
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vetenskapsrådet